User:AlphaUniform91/cerebrolysin
Cerebrolysin (developmental code name FPF-1070) is a mixture of peptides purified from pig brains, including (and not limited to) brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF).[1][2]
There is some tentative evidence of a beneficial effect on cognitive function in people with vascular dementia,[3] possibly through decreased beta-amyloid deposition.[4] Cerebrolysin is approved to treat strokes and dementia in 44 countries and is undergoing Phase III trials in multiple European countries.[5] It is also sold and used as a nootropic.
Mechanisms of Action[edit]
Manufacture[edit]
Composition[edit]
See Also[edit]
References[edit]
- ^ Windisch M, Gschanes A, Hutter-Paier B (1998). "Neurotrophic activities and therapeutic experience with a brain derived peptide preparation". J. Neural Transm. Suppl. 53: 289–98. PMID 9700665.
- ^ Menon PK, Muresanu DF, Sharma A, Mössler H, Sharma HS (2012). "Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals". CNS Neurol Disord Drug Targets. 11 (1): 40–9. doi:10.2174/187152712799960781. PMID 22229324.
- ^ Chen, N; Yang, M; Guo, J; Zhou, M; Zhu, C; He, L (31 January 2013). "Cerebrolysin for vascular dementia". The Cochrane Database of Systematic Reviews (1): CD008900. doi:10.1002/14651858.CD008900.pub2. PMID 23440834.
- ^ Masliah E, Díez-Tejedor E (2012). "The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders". Drugs Today. 48 Suppl A: 3–24. doi:10.1358/dot.2012.48(Suppl.A).1739716. PMID 22514792.
- ^ Berk, Camryn; Sabbagh, Marwan. "Successes and Failures for Drugs in Late-Stage Development for Alzheimer's Disease". Drugs & aging. 30 (10). doi:10.1007/s40266-013-0108-6. PMID 23943247. Retrieved 2018-07-25.